Product Information
IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB is a generic product labeled by Alembic Pharmaceuticals Inc., priced at $0.1488 per EA under NDC 62332005190. Its NADAC has been published 517 times since Nov 9, 2016.
FDA first approved this application on Oct 15, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
12.5; 150 mg/1; mg/1
Manufacturer
Alembic Pharmaceuticals Inc.NDC
62332005190
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
HYDROCHLOROTHIAZIDE; IRBESARTANApproval Type
Generic (ANDA)
FDA Application
ANDA091370FDA Approved
10/15/2012
TE Code
AB
On Market Since
5/23/2016
Pharmacological Classes
Price Statistics
The NADAC for IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB has been published 517 times since Nov 9, 2016, and over the history we have for it it has declined 48.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1488 per EA |
|---|---|
| All-time high | $0.3279 (Oct 14, 2020) |
| All-time low | $0.1308 (Jul 17, 2024) |
| 52-week high | $0.1696 |
| 52-week low | $0.1488 |
| Median price | $0.2155 |
| Average price | $0.2191 |
| Largest weekly change | +39.6% (Aug 21, 2024) |
| Weeks tracked | 517 |
| Tracking since | Nov 9, 2016 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 6% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Alembic Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Irbesartan and Hydrochlorothiazide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB?
The current National Average Drug Acquisition Cost (NADAC) for IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB, manufactured by Alembic Pharmaceuticals Inc., is $0.1488 per EA (NDC 62332005190), effective Sep 30, 2026.
How has the price of IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB changed over time?
Over the history we have for it, the NADAC for IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB has declined 48.3%. It has been tracked across 517 weekly CMS publications since Nov 9, 2016.
What are the highest and lowest recorded NADAC prices for IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB?
Since Nov 9, 2016, the NADAC for IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB has ranged from a low of $0.1308 (Jul 17, 2024) to a high of $0.3279 (Oct 14, 2020), with a median of $0.2155 per EA.
Are there cheaper alternatives to IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB, is $0.1405 per EA — about 6% below IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB.
Who manufactures IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB?
IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB (NDC 62332005190) is labeled by Alembic Pharmaceuticals Inc., and CMS classifies it as a generic product.